Clinical Features and Diagnosis of Intramedullary Spinal Cord Abscess in Adults: A Systematic Review
Citation Manager Formats
Make Comment
See Comments

Abstract
Background and Objectives Intramedullary spinal cord abscess (ISCA) was described 200 years ago but remains poorly understood and is often mistaken for immune-mediated or neoplastic processes. We present a systematic review of ISCA in adults, describing the clinical presentation, diagnostic features, treatment strategies, and outcomes.
Methods Database searches for intramedullary abscess were performed on April 15th 2019 and repeated February 9th 2022 using PubMed and EMBASE with two unpublished cases also included. Publications were independently reviewed for inclusion by two authors followed by adjudication. Data were abstracted using an online form then analyzed for predictors of disability.
Results 202 cases were included (median age 45 [interquartile range 31 – 58]; 70% male). 31% of those affected had no identified predisposing condition. The most common symptom was weakness (97%) and the median symptom duration prior to presentation was 10 days (interquartile range 5 – 42). MRI showed restricted diffusion in 100% of 8 cases where performed and enhancement in 99% of 153 cases where performed. The most common organisms were Mycobacterium tuberculosis (29%), Streptococcus (13%), and Staphylococcus (10%) species. All patients received antimicrobial therapy; surgical drainage was performed in 65%. At follow up (median 6 months), 12% had died, 69% were ambulatory, and 77% had improved compared to clinical nadir. Of those who underwent operative intervention, surgery within 24 hours of diagnosis was associated with increased likelihood of being ambulatory at follow-up compared to surgery after 24 hours (OR 4.44; 95% CI 1.26 – 15.61; p = 0.020).
Discussion ISCA is important to consider in any patient presenting with acute-subacute, progressive myelopathy. Immunocompromise and typical signs of infection (e.g., fever) are often absent. Diffusion restriction and gadolinium enhancement on MRI appear to be sensitive. Antimicrobial therapy with surgical drainage is the most common therapeutic approach, but morbidity remains substantial. If performed, urgent surgery may be more beneficial.
- Received August 5, 2021.
- Accepted in final form April 25, 2023.
- © 2023 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.